One-year retrospective analysis of anti-FXa apixaban and rivaroxaban levels demonstrates utility for management decisions in various urgent and nonurgent clinical situations

Online journal article in Hematopathology that offers 1.0 continuing education (CME) credit that can be used to fulfill CC Part II requirements.

Quantity:

Want to save more?

Log into see if you qualify for a lower rate.

Members

save $5.00 or more

Intended Audience: Pathologists, Residents, Clinical Scientists, Pathologist Assistants

Upon completion of this activity, you will be able to:

List established recommendations (as per the International Council for Standardization in Hematology (ICSH) consensus documents of 2018 and 2021) for...

Intended Audience: Pathologists, Residents, Clinical Scientists, Pathologist Assistants

Upon completion of this activity, you will be able to:

List established recommendations (as per the International Council for Standardization in Hematology (ICSH) consensus documents of 2018 and 2021) for monitoring or assessing direct oral anticoagulant (DOAC) plasma levels?
Summarize differences between warfarin and DOACs as anticoagulants, and why DOACs are used increasingly.
Identify clinical and laboratory features that may lead to requests for laboratory monitoring of DOAC plasma levels in addition to those recommended by the ICSH.

View More View Less